Inhaled Interferon Fails in Pivotal COVID Trial, but Developer Pushes On

(MedPage Today) -- SAN FRANCISCO -- A company hoping to market an inhalable formulation of interferon beta for viral lung diseases isn't dissuaded by phase III trial results in 623 hospitalized COVID-19 patients, which showed no statistically...
Source: MedPage Today Infectious Disease - Category: Infectious Diseases Source Type: news